Publications by authors named "P Durek"

Tissue-resident immune cells, such as innate lymphoid cells, mediate protective or detrimental immune responses at barrier surfaces. Upon activation by stromal or epithelial cell-derived alarmins, group 2 innate lymphoid cells (ILC2s) are a rapid source of type 2 cytokines, such as IL-5. However, due to the overlap in effector functions, it remains unresolved whether ILC2s are an essential component of the type 2 response or whether their function can be compensated by other cells, such as T cells.

View Article and Find Full Text PDF

Regulatory T cells (T cells) hold promise for sustainable therapy of immune disorders. Recent advancements in chimeric antigen receptor development and genome editing aim to enhance the specificity and function of T cells. However, impurities and functional instability pose challenges for the development of safe gene-edited T cell products.

View Article and Find Full Text PDF

In systemic lupus erythematosus, loss of immune tolerance, autoantibody production and immune complex deposition are required but not sufficient for organ damage. How inflammatory signals are initiated and amplified in the setting of autoimmunity remains elusive. Here we set out to dissect layers and hierarchies of autoimmune kidney inflammation to identify tissue-specific cellular hubs that amplify autoinflammatory responses.

View Article and Find Full Text PDF

Bone marrow plasma cells (BMPC) are the correlate of humoral immunity, consistently releasing antibodies into the bloodstream. It remains unclear if BMPC reflect different activation environments or maturation of their precursors. Here we define human BMPC heterogeneity and track the recruitment of antibody-secreting cells (ASC) from SARS-CoV-2 vaccine immune reactions to the bone marrow (BM).

View Article and Find Full Text PDF
Article Synopsis
  • * Variants of UNC93B1 (E92G and R336L) were found in patients with early-onset systemic lupus erythematosus (SLE), correlating with heightened inflammatory responses when stimulated by TLR7/TLR8 agonists.
  • * The E92G variant destabilizes the UNC93B1 protein, leading to increased TLR7 activity and type I interferon signaling, pointing to a potential therapeutic target for managing SLE by focusing on TLR7.
View Article and Find Full Text PDF